| Year |
Citation |
Score |
| 2020 |
Crawford JJ, Lee W, Johnson AR, Delatorre KJ, Chen J, Eigenbrot C, Heidmann J, Kakiuchi-Kiyota S, Katewa A, Kiefer JR, Liu L, Lubach JW, Misner D, Purkey H, Reif K, et al. Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity. Acs Medicinal Chemistry Letters. 11: 1588-1597. PMID 32832028 DOI: 10.1021/Acsmedchemlett.0C00249 |
0.395 |
|
| 2019 |
Patel S, Webster JD, Varfolomeev E, Kwon YC, Cheng JH, Zhang J, Dugger DL, Wickliffe KE, Maltzman A, Sujatha-Bhaskar S, Bir Kohli P, Ramaswamy S, Deshmukh G, Liederer BM, Fong R, ... ... Johnson A, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death and Differentiation. PMID 31101885 DOI: 10.1038/s41418-019-0347-0 |
0.327 |
|
| 2019 |
Hamilton GL, Chen H, Deshmukh G, Eigenbrot C, Fong R, Johnson A, Kohli PB, Lupardus PJ, Liederer BM, Ramaswamy S, Wang H, Wang J, Xu Z, Zhu Y, Vucic D, et al. Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group. Bioorganic & Medicinal Chemistry Letters. PMID 31000154 DOI: 10.1016/J.Bmcl.2019.04.014 |
0.414 |
|
| 2019 |
Zak M, Hanan EJ, Lupardus P, Brown DG, Robinson C, Siu M, Lyssikatos JP, Romero FA, Zhao G, Kellar T, Mendonca R, Ray NC, Goodacre SC, Crackett PH, McLean N, ... ... Johnson A, et al. Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. Bioorganic & Medicinal Chemistry Letters. PMID 30981576 DOI: 10.1016/J.Bmcl.2019.04.008 |
0.314 |
|
| 2018 |
Dengler HS, Wu X, Peng I, Rinderknecht CH, Kwon Y, Suto E, Kohli PB, Liimatta M, Barrett K, Lloyd J, Cain G, Briggs M, Addo S, Salmon G, Ubhayakar S, ... ... Johnson A, et al. Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma. Science Translational Medicine. 10. PMID 30463918 DOI: 10.1126/Scitranslmed.Aao2151 |
0.282 |
|
| 2018 |
Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA. Non-covalent inhibition of C481S Bruton's tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL. Blood. PMID 30018078 DOI: 10.1182/blood-2017-10-809020 |
0.385 |
|
| 2018 |
Lo YC, Liu T, Morrissey KM, Kakiuchi-Kiyota S, Johnson AR, Broccatelli F, Zhong Y, Joshi A, Altman RB. Computational Analysis of Kinase Inhibitor Selectivity using Structural Knowledge. Bioinformatics (Oxford, England). PMID 29985971 DOI: 10.1093/bioinformatics/bty582 |
0.381 |
|
| 2018 |
Huang CS, Oberbeck N, Hsiao YC, Liu P, Johnson AR, Dixit VM, Hymowitz SG. Crystal Structure of Ripk4 Reveals Dimerization-Dependent Kinase Activity. Structure (London, England : 1993). PMID 29706531 DOI: 10.1016/J.Str.2018.04.002 |
0.344 |
|
| 2018 |
Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo GM, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, et al. Discovery of GDC-0853, a Potent, Selective, and Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. Journal of Medicinal Chemistry. PMID 29457982 DOI: 10.1021/Acs.Jmedchem.7B01712 |
0.386 |
|
| 2018 |
Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S, Lesch J, Bents K, Everett C, Kohli PB, Linge S, ... ... Johnson AR, et al. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nature Communications. 9: 179. PMID 29330524 DOI: 10.1038/S41467-017-02672-0 |
0.346 |
|
| 2017 |
Liang J, Van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair WS, Chang C, Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Goodacre S, Ghilardi N, MacLeod C, Johnson A, et al. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model. Bioorganic & Medicinal Chemistry Letters. PMID 28830649 DOI: 10.1016/J.Bmcl.2017.08.022 |
0.392 |
|
| 2017 |
Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, et al. Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties. Acs Medicinal Chemistry Letters. 8: 608-613. PMID 28626519 DOI: 10.1021/Acsmedchemlett.7B00103 |
0.385 |
|
| 2017 |
Katewa A, Wang Y, Hackney JA, Huang T, Suto E, Ramamoorthi N, Austin CD, Bremer M, Chen JZ, Crawford JJ, Currie KS, Blomgren P, DeVoss J, DiPaolo JA, Hau J, ... Johnson A, et al. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. Jci Insight. 2: e90111. PMID 28405610 DOI: 10.1172/Jci.Insight.90111 |
0.327 |
|
| 2016 |
Castanedo GM, Blaquiere N, Beresini MH, Bravo B, Brightbill H, Chen J, Cui H, Eigenbrot C, Everett C, Feng JA, Godemann R, Gogol E, Hymowitz SG, Johnson AR, Kayagaki N, et al. Structure-based design of tricyclic NF-κB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K). Journal of Medicinal Chemistry. PMID 28005357 DOI: 10.1021/Acs.Jmedchem.6B01363 |
0.395 |
|
| 2016 |
Erickson RI, Schutt LK, Tarrant J, McDowell M, Liu L, Johnson AR, Lewin-Koh SC, Hedehus M, Ross J, Carano RA, Staflin K, Zhong F, Crawford J, Zhong S, Reif K, et al. BTK small molecule inhibitors induce a distinct pancreatic toxicity in rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 27821712 DOI: 10.1124/Jpet.116.236224 |
0.334 |
|
| 2016 |
Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, Barber T, Kaur G, Kuttikkatte SB, Leach OA, Desel C, Faergeman SL, Cheeseman J, Neville MJ, Sawcer S, ... ... Johnson AR, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Science Translational Medicine. 8: 363ra149. PMID 27807284 DOI: 10.1126/Scitranslmed.Aag1974 |
0.262 |
|
| 2016 |
Johnson AR, Kohli PB, Katewa A, Gogol E, Belmont LD, Choy R, Penuel E, Burton L, Eigenbrot C, Yu C, Ortwine DF, Bowman K, Franke Y, Tam C, Estevez A, et al. Battling Btk Mutants With Non-Covalent Inhibitors That Overcome Cys481 and Thr474 Mutations. Acs Chemical Biology. PMID 27571029 DOI: 10.1021/Acschembio.6B00480 |
0.405 |
|
| 2016 |
René O, Fauber BP, Barnard A, Chapman K, Deng Y, Eidenschenk C, Everett C, Gobbi A, Johnson AR, La H, Norman M, Salmon G, Summerhill S, Wong H. Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties. Bioorganic & Medicinal Chemistry Letters. PMID 27524313 DOI: 10.1016/j.bmcl.2016.07.081 |
0.352 |
|
| 2015 |
Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Eigenbrot C, Gallion S, Johnson AR, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, et al. Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. Bioorganic & Medicinal Chemistry Letters. PMID 26675441 DOI: 10.1016/J.Bmcl.2015.11.076 |
0.319 |
|
| 2015 |
Fauber BP, Gobbi A, Savy P, Burton B, Deng Y, Everett C, La H, Johnson AR, Lockey P, Norman M, Wong H. Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 25: 4109-13. PMID 26321361 DOI: 10.1016/j.bmcl.2015.08.028 |
0.306 |
|
| 2015 |
Fauber BP, René O, Deng Y, DeVoss J, Eidenschenk C, Everett C, Ganguli A, Gobbi A, Hawkins J, Johnson AR, La H, Lesch J, Lockey P, Norman M, Ouyang W, et al. Discovery of 1-{4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C (RORc or RORγ) Inverse Agonist. Journal of Medicinal Chemistry. 58: 5308-22. PMID 26061388 DOI: 10.1021/acs.jmedchem.5b00597 |
0.347 |
|
| 2015 |
Fauber BP, Gobbi A, Robarge K, Zhou A, Barnard A, Cao J, Deng Y, Eidenschenk C, Everett C, Ganguli A, Hawkins J, Johnson AR, La H, Norman M, Salmon G, et al. Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 25: 2907-12. PMID 26048793 DOI: 10.1016/j.bmcl.2015.05.055 |
0.344 |
|
| 2015 |
René O, Fauber BP, Boenig Gde L, Burton B, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, Kiefer JR, Liimatta M, Lockey P, Norman M, Ouyang W, Wallweber HA, et al. Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action. Acs Medicinal Chemistry Letters. 6: 276-81. PMID 25815138 DOI: 10.1021/ml500420y |
0.334 |
|
| 2014 |
Trani G, Barker JJ, Bromidge SM, Brookfield FA, Burch JD, Chen Y, Eigenbrot C, Heifetz A, Ismaili MH, Johnson A, Krülle TM, MacKinnon CH, Maghames R, McEwan PA, Montalbetti CA, et al. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK). Bioorganic & Medicinal Chemistry Letters. 24: 5818-23. PMID 25455497 DOI: 10.1016/J.Bmcl.2014.10.020 |
0.388 |
|
| 2014 |
van Niel MB, Fauber BP, Cartwright M, Gaines S, Killen JC, René O, Ward SI, de Leon Boenig G, Deng Y, Eidenschenk C, Everett C, Gancia E, Ganguli A, Gobbi A, Hawkins J, ... Johnson AR, et al. A reversed sulfonamide series of selective RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 24: 5769-76. PMID 25453817 DOI: 10.1016/j.bmcl.2014.10.037 |
0.366 |
|
| 2014 |
Fauber BP, René O, de Leon Boenig G, Burton B, Deng Y, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, La H, Liimatta M, Lockey P, Norman M, Ouyang W, et al. Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 24: 3891-7. PMID 25017032 DOI: 10.1016/j.bmcl.2014.06.048 |
0.318 |
|
| 2014 |
Burch JD, Lau K, Barker JJ, Brookfield F, Chen Y, Chen Y, Eigenbrot C, Ellebrandt C, Ismaili MH, Johnson A, Kordt D, MacKinnon CH, McEwan PA, Ortwine DF, Stein DB, et al. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors. Journal of Medicinal Chemistry. 57: 5714-27. PMID 24918870 DOI: 10.1021/Jm500550E |
0.395 |
|
| 2014 |
Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proceedings of the National Academy of Sciences of the United States of America. 111: 8025-30. PMID 24843152 DOI: 10.1073/Pnas.1401180111 |
0.306 |
|
| 2014 |
Pastor RM, Burch JD, Magnuson S, Ortwine DF, Chen Y, De La Torre K, Ding X, Eigenbrot C, Johnson A, Liimatta M, Liu Y, Shia S, Wang X, Wu LC, Pei Z. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors. Bioorganic & Medicinal Chemistry Letters. 24: 2448-52. PMID 24767842 DOI: 10.1016/j.bmcl.2014.04.023 |
0.412 |
|
| 2014 |
Fauber BP, René O, Burton B, Everett C, Gobbi A, Hawkins J, Johnson AR, Liimatta M, Lockey P, Norman M, Wong H. Identification of tertiary sulfonamides as RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 24: 2182-7. PMID 24685544 DOI: 10.1016/j.bmcl.2014.03.038 |
0.314 |
|
| 2014 |
Fauber BP, Johnson AR, Bowerman S, Burton B, Colebrook A, Flynn A, Harrold G, Huhn S, Jones G, Lockey P, Norman M, René O, Wong H. Syntheses of [3H2]T0901317 and a labeled structural isomer, and characterization of the dispersed labeled compounds via 19F NMR Journal of Labelled Compounds and Radiopharmaceuticals. 57: 57-60. DOI: 10.1002/jlcr.3138 |
0.228 |
|
| 2013 |
Fauber BP, de Leon Boenig G, Burton B, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, Liimatta M, Lockey P, Norman M, Ouyang W, René O, Wong H. Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc. Bioorganic & Medicinal Chemistry Letters. 23: 6604-9. PMID 24239186 DOI: 10.1016/j.bmcl.2013.10.054 |
0.337 |
|
| 2013 |
MacKinnon CH, Lau K, Burch JD, Chen Y, Dines J, Ding X, Eigenbrot C, Heifetz A, Jaochico A, Johnson A, Kraemer J, Kruger S, Krülle TM, Liimatta M, Ly J, et al. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK). Bioorganic & Medicinal Chemistry Letters. 23: 6331-5. PMID 24138940 DOI: 10.1016/j.bmcl.2013.09.069 |
0.409 |
|
| 2013 |
Labadie S, Barrett K, Blair WS, Chang C, Deshmukh G, Eigenbrot C, Gibbons P, Johnson A, Kenny JR, Kohli PB, Liimatta M, Lupardus PJ, Shia S, Steffek M, Ubhayakar S, et al. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 5923-30. PMID 24042009 DOI: 10.1016/J.Bmcl.2013.08.082 |
0.432 |
|
| 2013 |
Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, Smith J, Lai Y, Zhou A, Zhang B, Yang W, Williams K, Macleod C, Hurley CA, Kulagowski JJ, ... ... Johnson AR, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. Journal of Immunology (Baltimore, Md. : 1950). 191: 2205-16. PMID 23894201 DOI: 10.4049/Jimmunol.1202859 |
0.277 |
|
| 2013 |
Liang J, Tsui V, Van Abbema A, Bao L, Barrett K, Beresini M, Berezhkovskiy L, Blair WS, Chang C, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, et al. Lead identification of novel and selective TYK2 inhibitors. European Journal of Medicinal Chemistry. 67: 175-87. PMID 23867602 DOI: 10.1016/J.Ejmech.2013.03.070 |
0.397 |
|
| 2013 |
Liang J, van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair W, Chang C, Delarosa D, DeVoss J, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, et al. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. Journal of Medicinal Chemistry. 56: 4521-36. PMID 23668484 DOI: 10.1021/Jm400266T |
0.39 |
|
| 2013 |
Zak M, Hurley CA, Ward SI, Bergeron P, Barrett K, Balazs M, Blair WS, Bull R, Chakravarty P, Chang C, Crackett P, Deshmukh G, DeVoss J, Dragovich PS, Eigenbrot C, ... ... Johnson A, et al. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. Journal of Medicinal Chemistry. 56: 4764-85. PMID 23659214 DOI: 10.1021/Jm4004895 |
0.39 |
|
| 2013 |
Hurley CA, Blair WS, Bull RJ, Chang C, Crackett PH, Deshmukh G, Dyke HJ, Fong R, Ghilardi N, Gibbons P, Hewitt PR, Johnson A, Johnson T, Kenny JR, Kohli PB, et al. Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1. Bioorganic & Medicinal Chemistry Letters. 23: 3592-8. PMID 23642482 DOI: 10.1016/J.Bmcl.2013.04.018 |
0.397 |
|
| 2013 |
Johnson AR. In Vitro and In Vivo Assays Drug Discovery: Practices, Processes, and Perspectives. 67-98. DOI: 10.1002/9781118354483.ch3 |
0.257 |
|
| 2012 |
Labadie S, Dragovich PS, Barrett K, Blair WS, Bergeron P, Chang C, Deshmukh G, Eigenbrot C, Ghilardi N, Gibbons P, Hurley CA, Johnson A, Kenny JR, Kohli PB, Kulagowski JJ, et al. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2. Bioorganic & Medicinal Chemistry Letters. 22: 7627-33. PMID 23107482 DOI: 10.1016/J.Bmcl.2012.10.008 |
0.407 |
|
| 2012 |
de Leon-Boenig G, Bowman KK, Feng JA, Crawford T, Everett C, Franke Y, Oh A, Stanley M, Staben ST, Starovasnik MA, Wallweber HJ, Wu J, Wu LC, Johnson AR, Hymowitz SG. The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site. Structure (London, England : 1993). 20: 1704-14. PMID 22921830 DOI: 10.1016/J.Str.2012.07.013 |
0.368 |
|
| 2012 |
Zak M, Mendonca R, Balazs M, Barrett K, Bergeron P, Blair WS, Chang C, Deshmukh G, Devoss J, Dragovich PS, Eigenbrot C, Ghilardi N, Gibbons P, Gradl S, Hamman C, ... ... Johnson A, et al. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. Journal of Medicinal Chemistry. 55: 6176-93. PMID 22698084 DOI: 10.1021/Jm300628C |
0.404 |
|
| 2012 |
Kulagowski JJ, Blair W, Bull RJ, Chang C, Deshmukh G, Dyke HJ, Eigenbrot C, Ghilardi N, Gibbons P, Harrison TK, Hewitt PR, Liimatta M, Hurley CA, Johnson A, Johnson T, et al. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. Journal of Medicinal Chemistry. 55: 5901-21. PMID 22591402 DOI: 10.1021/Jm300438J |
0.43 |
|
| 2012 |
Liu Y, Beresini MH, Johnson A, Mintzer R, Shah K, Clark K, Schmidt S, Lewis C, Liimatta M, Elliott LO, Gustafson A, Heise CE. Case studies of minimizing nonspecific inhibitors in HTS campaigns that use assay-ready plates. Journal of Biomolecular Screening. 17: 225-36. PMID 21940710 DOI: 10.1177/1087057111421525 |
0.326 |
|
| 2011 |
Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, ... Johnson AR, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 471: 110-4. PMID 21368834 DOI: 10.1038/Nature09779 |
0.272 |
|
| 2011 |
Li JJ, Johnson AR. Selective MMP13 inhibitors. Medicinal Research Reviews. 31: 863-94. PMID 20196103 DOI: 10.1002/med.20204 |
0.381 |
|
| 2010 |
Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, ... ... Johnson AR, et al. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorganic & Medicinal Chemistry Letters. 20: 576-80. PMID 20005097 DOI: 10.1016/J.Bmcl.2009.11.081 |
0.677 |
|
| 2008 |
Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK. Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Journal of Medicinal Chemistry. 51: 835-41. PMID 18251495 DOI: 10.1021/Jm701274V |
0.628 |
|
| 2007 |
Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C, Baragi V, Lesch C, Roark WH, Wilson M, Datta K, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. The Journal of Biological Chemistry. 282: 27781-91. PMID 17623656 DOI: 10.1074/Jbc.M703286200 |
0.662 |
|
| 2001 |
Johnson AR, Marletta MA, Dyer RD. Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol. Biochemistry. 40: 7736-45. PMID 11412128 DOI: 10.1021/Bi002343F |
0.686 |
|
| 2000 |
Johnson LL, Pavlovsky AG, Johnson AR, Janowicz JA, Man CF, Ortwine DF, Purchase CF, White AD, Hupe DJ. A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloproteinase-3) catalysis and inhibition. The Journal of Biological Chemistry. 275: 11026-33. PMID 10753905 DOI: 10.1074/jbc.275.15.11026 |
0.41 |
|
| 1999 |
Wang Y, Johnson AR, Ye QZ, Dyer RD. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. The Journal of Biological Chemistry. 274: 33043-9. PMID 10551873 DOI: 10.1074/Jbc.274.46.33043 |
0.62 |
|
| 1998 |
Johnson AR, Chen YW, Dekker EE. Investigation of a catalytic zinc binding site in Escherichia coli L-threonine dehydrogenase by site-directed mutagenesis of cysteine-38. Archives of Biochemistry and Biophysics. 358: 211-21. PMID 9784233 DOI: 10.1006/Abbi.1998.0845 |
0.531 |
|
| 1998 |
Johnson AR, Dekker EE. Site-directed mutagenesis of histidine-90 in Escherichia coli L-threonine dehydrogenase alters its substrate specificity. Archives of Biochemistry and Biophysics. 351: 8-16. PMID 9500838 DOI: 10.1006/Abbi.1997.0501 |
0.504 |
|
| 1998 |
Clark-Baldwin K, Johnson AR, Chen YW, Dekker EE, Penner-Hahn JE. Structural characterization of the zinc site in Escherichia coli L-threonine dehydrogenase using extended X-ray absorption fine structure spectroscopy Inorganica Chimica Acta. 275: 215-221. DOI: 10.1016/S0020-1693(97)06107-0 |
0.532 |
|
| 1996 |
Johnson AR, Dekker EE. Woodward's reagent K inactivation of Escherichia coli L-threonine dehydrogenase: increased absorbance at 340-350 nm is due to modification of cysteine and histidine residues, not aspartate or glutamate carboxyl groups. Protein Science : a Publication of the Protein Society. 5: 382-90. PMID 8745417 DOI: 10.1002/Pro.5560050223 |
0.505 |
|
| Show low-probability matches. |